DaVita and Humana Partner to Expand Chronic Kidney Disease Care

Key Facts

In a move reflecting the growing shift toward outcome-based healthcare, DaVita Inc. has announced a value-based care agreement with Humana Inc. to serve Medicare Advantage members. The partnership aims to provide coordinated care for over 10,000 patients suffering from chronic kidney disease (CKD) stages 3B through 5. The collaboration focuses on intervening earlier in the disease progression to stabilize kidney function and slow decline through interdisciplinary support.

This strategic partnership strengthens the position of both entities in the healthcare sector, expanding DaVita's patient base and enhancing Humana's value-based care offerings. Per market data, Humana (HUM) shares closed at $386.61 on August 24, 2026, with the stock trading between a session low of $379.27 and a high of $389.85.

Investors are monitoring how this strategic expansion will impact Humana's financial performance, especially with the stock at $386.61 (close August 24, 2026). Looking at the economic calendar, there are no immediate upcoming catalysts for the healthcare sector in the next few days, leaving the focus on the operational execution of this partnership and its ability to reduce total care costs.